ArticleMicrobial cell factories2025
Further characterization and engineering of an 11-amino acid motif for enhancing recombinant soluble protein expression.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- High-level fed-batch production of recombinant type II cholesterol oxidase fromBiotechnology reports (Amsterdam, Netherlands) · 2026Article
- Engineering of a Carbonic Anhydrase fromInternational journal of molecular sciences · 2026Article
- A standardized set of pNX vectors for enhanced soluble expression of recombinant proteins in E. coli using small fusion tags.Microbial cell factories · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEscherichia coli (E. coli) is a popular system for recombinant protein production, owing to its low cost and availability of genetic tools. However, the expression of soluble recombinant proteins remains an issue. As such, various solubility-enhancing and yield-improving methods such as the addition of fusion tags have been developed. This study focuses on a small solubility tag (NT11), derived from the N-terminal domain of a duplicated carbonic anhydrase from Dunaliella species. The small size of NT11 (< 10 kDa) lowers the chance of protein folding interference and post-translation removal requirement, which ultimately minimizes cost of production.
resultsA comprehensive analysis was performed to improve the characteristics of the 11-amino acid tag. By investigating the alanine-scan library of NT11, we achieved at least a two-fold increase in protein yield for three different proteins and identified key residues for further development. We also demonstrated that the NT11 tag is not limited to the N-terminal position and can function at either the N- or C-terminal of the protein, providing flexibility in designing constructs. With these new insights, we have successfully doubled the recombinant soluble protein yields of valuable growth factors, such as fibroblast growth factor 2 (FGF2) and human epidermal growth factor (hEGF) in E. coli.
conclusionThe further characterisation and development of the NT11 tag have provided valuable insights into the optimisation process for such small tags and expanded our understanding of its potential applications. The ability of the NT11 tag to be positioned at either the N- or C- termini within the protein construct without compromising its effectiveness to enhance soluble recombinant protein yields, makes it a valuable tool across a diverse range of proteins. Collectively, these findings demonstrate a promising approach to simplify and enhance the efficiency of soluble recombinant protein production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.